etherna immunotherapies NV ("etherna"), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announces a strategic collaboration with Dropshot Therapeutics ...

Chien and Marijn Dekkers' Dropshot is serving up an RNA pact worth up to $950 million for Etherna Immunotherapies.

The eTheRNA research team encapsulated a novel mixture of mRNA coding for three proteins (IL-21, IL-7, and 4-1BBL) in the selected LNPs.

Almirall has partnered with etherna for the development of mRNA-based therapies for the treatment of severe skin diseases, including nonmelanoma skin cancer, the companies announced in a press ...

Almirall and etherna share the vision that intradermal application of LNP-formulated mRNA is a highly promising strategy to bring novel, efficacious new treatment options that will deliver huge ...

The positions in the table below reflect the eTheRNA immunotherapies NV's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position ...

NIEL, Belgium and BOSTON , Jan. 9, 2025 /CNW/ -- etherna immunotherapies NV ("etherna"), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announces a ...

etherna immunotherapies NV ("etherna"), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announces a strategic collaboration with Dropshot Therapeutics ...

The collaboration builds on Dropshot's prior evaluation of etherna's mRNA and LNP platforms and is intended to create novel proprietary therapeutics based on etherna's mRNA and its LNP ...